Masashi Nishimi

Clinical Lead
Sanofi K.K, Tokyo, Japan
Tokyo, Tokyo, Japan

Presentation(s):

• PB1322 - Post hoc analysis of ADAMTS13 activity and inhibitors in a phase 2/3 study in Japanese patients with iTTP treated with caplacizumab

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT